Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAI) and p-methylthioamphetamine (MTA)

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 3, 1996, Pages 1261-1267

  Li, Qian ^a   Murakami, Ingrid ^a   Stall, Scott ^a   Levy, Andrew D ^a   Brownfield, Mark S ^b   Nichols, David E ^c   Van De Kar, Louis D ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1,3 BENZODIOXOL 5 YL) 2 (METHYLAMINO)BUTANE; 4 METHYLTHIOAMPHETAMINE; 5 METHOXY 6 METHYL 2 AMINOINDAN; CORTICOSTERONE; CORTICOTROPIN; DOPAMINE; DOPAMINE 2 RECEPTOR; FLUOXETINE; OXYTOCIN; PROLACTIN; RENIN; SEROTONIN; SEROTONIN AGONIST; UNCLASSIFIED DRUG; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYCARDIA; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; DOSE RESPONSE; DRUG INHIBITION; HORMONE RELEASE; HYPOTENSION; MALE; NERVE ENDING; NEUROTRANSMISSION; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RAT; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; VASOPRESSIN BLOOD LEVEL;

3,4-METHYLENEDIOXYAMPHETAMINE; AMPHETAMINES; ANIMALS; FLUOXETINE; INDANS; MALE; OXYTOCIN; PROLACTIN; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; VASOPRESSINS;

EID: 0030431323     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. ALPER, R. H., LEE, C. AND BRODY, M. J.: Hemodynamic pharmacology of p-chloroamphetamine, a serotonin agonist, in conscious rats. J. Pharmacol. Exp. Ther. 243: 446-454, 1987.
2. BAGDY, G., SVED, A. F., MURPHY, D. L. AND SZEMEREDI, K.: Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists. Eur. J. Pharmacol. 210: 285-289, 1992.
3. BERGER, U. V., GU, X. F. AND AZMITIA, E. C.: The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur. J. Pharmacol. 215: 153-160, 1992.
4. BERTOLINO, S., JULIEN, C., MEDEIROS, I. A., VINCENT, M. AND BARRES, C.: Pressure-dependent renin release and arterial pressure maintenance in conscious rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 266: R1032-R1037, 1994.
5. BROWNFIELD, M. S., ARMSTRONG, J., RITTENHOUSE, P. A., LI, Q., LEVY, A. D. AND VAN DE KAR, L. D.: Pharmacological differentiation of serotonergic (5-HT) stimulation of oxytocin and vasopressin secretion in the conscious rat (Abstract). Neuroscience 18: 823 (#346.7), 1992.
6. BROWNFIELD, M. S., GREATHOUSE, J., LORENS, S. A., ARMSTRONG, J., URBAN, J. H. AND VAN DE KAR, L. D.: Neuropharmacological characterization of serotoninergic stimulation of vasopressin secretion in conscious rats. Neuroendocrinology 47: 277-283, 1988.
7. BROWNFIELD, M. S., RUTTENHOUSE, P. A., VAN DE KAR, L. D. AND SAYDOFF, J. A.: Brain angiotensin Mechanisms mediate the serotonin (5-HT)-induced stimulation of vasopressin (VP), but not oxytocin (OT) in conscious male rats (Abstract). Soc. Neurosci. 19: 1993.
8. BURRIS, T. P., NGUYEN, D. N., SMITH, S, G. AND FREEMAN, M. E.: The stimulatory and inhibitory effects of dopamine on prolactin secretion involve different G-proteins. Endocrinology 130: 926-932, 1992.
9. CALLAWAY, C. W., WING, L. L., NICHOLS, D. E. AND GEYER, M. A.: Suppression of behavioral activity by norfenfluramine and related drugs in rats is not mediated by serotonin release. Psychopharmacology (Berl) 111: 169-178, 1993.
10. COSTA, E., NAIMZADA, K. M. AND REVUELTA, A.: Effect of phenmetrazine, aminorex and (±) p-chloroamphetamine on the motor activity and turnover rate of brain catecholamines. Br. J. Pharmacol. 43: 570-579, 1971.
11. CROWLEY, W. R., PARKER, S. L., ARMSTRONG, W. E., WANG, W. AND GROSVENOR, C. E.: Excitatory and inhibitory dopaminergic regulation of oxytocin secretion in the lactating rat: Evidence for respective mediation by D-1 and D-2 dopamine receptor subtypes. Neuroendocrinology 53: 493-502, 1991.
12. 2 receptor density and the prolactin suppressive potency of agonists. Eur. J. Pharmacol. 243: 296-299, 1993.
13. FATTACCINI, C. M., GOZLAN, H. AND HAMON, M.: Differential effects of d-fenfluramine and p-chloroamphetamine on H75/12-induced depletion of 5-hydroxytryptamine and dopamine in the rat brain. Neuropharmacology 30: 15-23, 1991.
14. FULLER, R. W.: Effects of p-chloroamphetamine on brain serotonin neurons. Neurochem. Res. 17: 449-456, 1992.
15. FULLER, R. W. AND SNODDY, H. D.: Effect of serotonin-releasing drugs on serum corticosterone concentration in rats. Neuroendocrinology 31: 96-100, 1980.
16. FULLER, R. W. AND SNODDY, H. D.: Central dopamine receptors mediating pergolide-induced elevation of serum corticosterone in rats. Characterization by the use of antagonists. Neuropharmacology 23: 1389-1394, 1984.
17. FULLER, R. W., SNODDY, H. D. AND CLEMENS, J. A.: Elevation of serum prolactin acutely after administration of P-chloroamphetamine in rats. Endocr. Res. Commun. 7: 77-85, 1980.
18. FULLER, R. W., SNODDY, H. D. AND ROBERTSON, D. W.: Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: Uptake inhibition versus release. Pharmacol. Biochem. Behav. 30: 715-721, 1988.
19. HUANG, X., MARONA-LEWICKA, D. AND NICHOLS, D. E.: p-Methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur. J. Pharmacol. 229: 31-38, 1992.
20. IOVINO, M. AND STEARDO, L.: Effect of substances influencing brain serotonergic transmission on plasma vasopressin levels in the rat. Eur. J. Pharmacol. 113: 99-103, 1985.
21. IYER, R. N., SPROUSE, J. S., AGHAJANIAN, G. K., ROTH, R. H. AND BRADBERRY, C. W.: Tryptophan pretreatment augmentation of p-chloroamphetamine-induced serotonin and dopamine release and reduction of long-term neurotoxicity. Biochem. Pharmacol. 48: 1501-1508, 1994.
22. JEZOVA, D. AND VIGAS, M.: Apomorphine injection stimulates β-endorphin, adrenocorticotropin, and cortisol release in healthy man. Psychoneuroendocrinology 6: 479-485, 1988.
23. 3H]Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur. J. Pharmacol. 200: 9-16, 1991.
24. KUHN, D. M., WOLF, W. A. AND YOUDIM, M. B. H.: 5-Hydroxytryptamine release in vivo from a cytoplasmic pool: Studies on the 5-HT behavioural syndrome in reserpinized rats. Br. J. Pharmacol. 84: 121-129, 1985.
25. LEVY, A. D., BAUMANN, M. H. AND VAN DE KAR, L. D.: Monoaminergic regulation of neuroendocrine function and its modification by cocaine. Frontiers in Neuroendocrinology 15: 1-72, 1994a.
26. 1A agonist, 8-OH-DPAT. Neuropharmacology 33: 335-342, 1994b.
27. 1A agonist 8-OH-DPAT in male rats. Brain Res. 630: 148-156, 1993.
28. MARONA-LEWICKA, D. AND NICHOLS, D. E.: Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. Eur. J. Pharmacol. 258: 1-13, 1994.
29. MCELROY, J. F., MILLER, J. M. AND MEYER, J. S.: Fenfluramine, p-chloroamphetamine and p-fluoroamphetamine stimulation of pituitary-adrenocortical activity in rat: Evidence for differences in site and mechanism of action. J. Pharmacol. Exp. Ther. 228: 593-599, 1984.
30. 3H-5-hydroxytryptamine. Pharmacol. Biochem. Behav. 38: 505-512, 1991.
31. 2 receptors elicits prolactin secretion and catalepsy. J. Pharmacol. Exp. Ther. 275: 885-898, 1995.
32. MONTES, R. AND JOHNSON, A. K.: Efferent mechanisms mediating renal sodium and water excretion induced by centrally administered serotonin. Am. J. Physiol. Regul. Integr. Comp. Physiol. 259: R1267-R1273, 1990.
33. NICHOLS, D. E., MARONA-LEWICKA, D., HUANG, X. AND JOHNSON, M. P.: Novel serotonergic agents. Drug Design and Discovery 9: 299-312, 1993.
34. PARK, S. B. G. AND COWEN, P. J.: Effect of pindolol on the prolactin response to d-fenfluramine. Psychopharmacology (Berl) 118: 471-474, 1995.
35. PERGOLA, P. E., SVED, A. F., VOOGT, J. L. AND ALPER, R. H.: Effect of serotonin on vasopressin release: A comparison to corticosterone, prolactin and renin. Neuroendocrinology 57: 550-558, 1993.
36. PUIG DE PARADA, M., PARADA, M. A., POTHOS, E. AND HOEBEL, B. G.: d-Fenfluramine, but not d-norfenfluramine, uses calcium to increase extracellular serotonin. Life Sci. 56: PL415-PL420, 1995.
37. RITTENHOUSE, P. A., BAKKUM, E. A., LEVY, A. D., LI, Q., YRACHETA, J. M., KUNIMOTO, K. AND VAN DE KAR, L. D.: Central stimulation of renin secretion through serotonergic, noncardiovascular mechanisms. Neuroendocrinology 60: 205-214, 1994.
38. RUDNICK, G. AND WALLS, S. C.: p-Chloroamphetamine induces serotonin release through serotonin transporters. Biochemistry 31: 6710-6718, 1992.
39. RUDNICK, G. AND WALLS, S. C.: Non-neurotoxic amphetamine derivatives release serotonin through serotonin transporters. Mol. Pharmacol. 43: 271-276, 1993.
40. SAYDOFF, J. A., LEANZA, F., CARNES, M. AND BROWNFIELD, M. S.: Central serotonin induces vasopressin and oxytocin secretion and a specific pattern of c-Fos expression in rat brain (Abstract). Soc. Neurosci. 18: 823 (#346.5), 1992.
41. SAYDOFF, J. A., RITTENHOUSE, P. A., CARNES, M., ARMSTRONG, J., VAN DE KAR, L. D. AND BROWNFIELD, M. S.: Neuroendocrine and cardiovascular activation by serotonin: Selective role of brain angiotensin in vasopressin secretion. Am. J. Physiol. Regul. (Endocrinol. Metab. 33) 270: E513-E521, 1996.
42. SAYDOFF, J. A., RITTENHOUSE, P. A., VAN DE KAR, L. D. AND BROWNFIELD, M. S.: Enhanced serotonergic transmission stimulates oxytocin secretion in conscious male rats. J. Pharmacol. Exp. Ther. 257: 95-99, 1991.
43. STEEL, R. G. D. AND TORRIE, J. H.: Principles and Procedures of Statistics with Special Reference to the Biological Sciences, McGraw-Hill, New York, 1960.
44. VAN DE KAR, L. D., RICHARDSON, K. D. AND URBAN, J. H.: Serotonin and norepinephrine-dependent effects of fenfluramine on plasma renin activity in conscious male rats. Neuropharmacology 24: 487-494, 1985a.
45. VAN DE KAR, L. D., RITTENHOUSE, P. A., LI, Q., LEVY, A. D. AND BROWNFIELD, M. S.: Hypothalamic paraventricular, but not supraoptic, neurons mediate the serotonergic stimulation of oxytocin secretion. Brain Res. Bull. 36: 45-50, 1995.
46. VAN DE KAR, L. D., URBAN, J. H., RICHARDSON, K. D. AND BETHEA, C. L.: Pharmacological studies on the serotoninergic and nonserotonin-mediated stimulation of prolactin and corticosterone secretion by fenfluramine. Effects of pretreatment with fluoxetine, indalpine, PCPA, and 1-tryptophan. Neuroendocrinology 41: 283-288, 1985b.
47. VAN DE KAR, L. D., WILKINSON, C. W., SKROBIK, Y., BROWNFIELD, M. S. AND GANONG, W. F.: Evidence that serotonergic neurons in the dorsal raphe nucleus exert a stimulatory effect on the secretion of renin but not of corticosterone. Brain Res. 235: 233-243, 1982.
48. VAN DE KAR, L. D. AND BETHEA, C. L.: Pharmacological evidence that serotonergic stimulation of prolactin secretion is mediated via the dorsal raphe nucleus. Neuroendocrinology 35: 225-230, 1982.
49. WONG, D. T., BYMASTER, F. P., REID, L. R., FULLER, R. W. AND PERRY, K. W.: Inhibition of serotonin uptake by optical isomers of fluoxetine. Drug Dev. Res. 6: 397-403, 1985.
50. WONG, D. T., BYMASTER, F. P., REID, L. R. AND THRELKELD, P. G.: Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem. Pharmacol. 32: 1287-1293, 1983.